Literature DB >> 26882885

Viral hepatitis: Drug-drug interactions in HCV treatment--the good, the bad and the ugly.

Jacob A Langness1, Gregory T Everson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26882885     DOI： 10.1038/nrgastro.2016.24

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Evidence for association between hepatitis C virus seropositivity and coronary artery disease.

Authors:  C Vassalle; S Masini; F Bianchi; G C Zucchelli
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

2.  Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned.

Authors:  David J Back; David M Burger
Journal:  Gastroenterology       Date:  2015-09-28       Impact factor: 22.682

Review 3.  Cardiovascular diseases and HCV infection: a simple association or more?

Authors:  Salvatore Petta; Fabio Salvatore Macaluso; Antonio Craxì
Journal:  Gut       Date:  2013-12-02       Impact factor: 23.059

4.  Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.

Authors:  Micaela B Reddy; Yuan Chen; Joshua O Haznedar; Jennifer Fretland; Steven Blotner; Patrick Smith; Jonathan Q Tran
Journal:  Clin Pharmacokinet       Date:  2012-07-01       Impact factor: 6.447

5.  Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort.

Authors:  Christoph Höner Zu Siederdissen; Benjamin Maasoumy; Fiona Marra; Katja Deterding; Kerstin Port; Michael P Manns; Markus Cornberg; David Back; Heiner Wedemeyer
Journal:  Clin Infect Dis       Date:  2015-11-26       Impact factor: 9.079

6.  Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.

Authors:  Leonard B Seeff; Teresa M Curto; Gyongyi Szabo; Gregory T Everson; Herbert L Bonkovsky; Jules L Dienstag; Mitchell L Shiffman; Karen L Lindsay; Anna S F Lok; Adrian M Di Bisceglie; William M Lee; Marc G Ghany
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

7.  Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.

Authors:  Sophie Renet; Marie-Camille Chaumais; Teresa Antonini; Alexandre Zhao; Laure Thomas; Arnaud Savoure; Didier Samuel; Jean-Charles Duclos-Vallée; Vincent Algalarrondo
Journal:  Gastroenterology       Date:  2015-08-04       Impact factor: 22.682

8.  Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.

Authors:  Julie C Lauffenburger; Christina L Mayer; Roy L Hawke; Kim L R Brouwer; Michael W Fried; Joel F Farley
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-10       Impact factor: 2.566

Review 9.  Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection.

Authors:  Omar El-Sherif; Saye Khoo; Caroline Solas
Journal:  Curr Opin HIV AIDS       Date:  2015-09       Impact factor: 4.283

Review 10.  Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy.

Authors:  Prajakta S Badri; Jennifer R King; Akshanth R Polepally; Barbara H McGovern; Sandeep Dutta; Rajeev M Menon
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447
  10 in total
  2 in total

1.  Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort.

Authors:  Miriam Coghlan; Aisling O'Leary; Gail Melanophy; Colm Bergin; Suzanne Norris
Journal:  Int J Clin Pharm       Date:  2019-07-11

2.  Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.

Authors:  Loreta A Kondili; Giovanni Battista Gaeta; Donatella Ieluzzi; Anna Linda Zignego; Monica Monti; Andrea Gori; Alessandro Soria; Giovanni Raimondo; Roberto Filomia; Alfredo Di Leo; Andrea Iannone; Marco Massari; Romina Corsini; Roberto Gulminetti; Alberto Gatti Comini; Pierluigi Toniutto; Denis Dissegna; Francesco Paolo Russo; Alberto Zanetto; Maria Grazia Rumi; Giuseppina Brancaccio; Elena Danieli; Maurizia Rossana Brunetto; Liliana Elena Weimer; Maria Giovanna Quaranta; Stefano Vella; Massimo Puoti
Journal:  PLoS One       Date:  2017-02-28       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.